Barrett's esophagus and esophageal cancer: An overview

Vincenza Conteduca, Domenico Sansonno, Giuseppe Ingravallo, Stefania Marangi, Sabino Russi, Gianfranco Lauletta, Franco Dammacco

Research output: Contribution to journalArticle

Abstract

Although esophageal cancer (EC) is the eighth most common cancer in several European countries, it is one of deadliest worldwide. The most frequent predisposing factor implicated in its development is Barrett's esophagus (BE), an acquired metaplastic transformation of the esophageal lining cells from normal squamous epithelium into specialised or intestinal-like columnar epithelium. The major risk factor for BE is gastroesophageal reflux disease. Although BE is in itself a benign and often asymptomatic disorder, its clinical importance stems from the recognition that it represents the main precursor lesion for the development of esophageal adenocarcinoma (AC), a tumor that is rapidly increasing especially in developed countries and is associated with a low survival rate. This paper provides an overview of the epidemiology and natural history of BE as well as of the possible pathogenetic mechanisms underlying the development of BE and its progressive transition to AC. New diagnostic tests are described, recommendations for screening and surveillance are provided and surgical and ablative procedures to treat dysplastic lesions and early neoplasia are discussed. Claimed chemopreventive agents and biomarkers that in the near future may help identify people with a higher risk of EC are also considered.

Original languageEnglish
Pages (from-to)414-424
Number of pages11
JournalInternational Journal of Oncology
Volume41
Issue number2
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Barrett Esophagus
Esophageal Neoplasms
Adenocarcinoma
Epithelium
Neoplasms
Gastroesophageal Reflux
Routine Diagnostic Tests
Developed Countries
Causality
Epidemiology
Survival Rate
Biomarkers
Epithelial Cells

Keywords

  • Adenocarcinoma
  • Barrett's esophagus
  • Biomarkers
  • Esophageal cancer
  • Gastro-esophageal reflux disease
  • Proton pump inhibitors
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Conteduca, V., Sansonno, D., Ingravallo, G., Marangi, S., Russi, S., Lauletta, G., & Dammacco, F. (2012). Barrett's esophagus and esophageal cancer: An overview. International Journal of Oncology, 41(2), 414-424. https://doi.org/10.3892/ijo.2012.1481

Barrett's esophagus and esophageal cancer : An overview. / Conteduca, Vincenza; Sansonno, Domenico; Ingravallo, Giuseppe; Marangi, Stefania; Russi, Sabino; Lauletta, Gianfranco; Dammacco, Franco.

In: International Journal of Oncology, Vol. 41, No. 2, 08.2012, p. 414-424.

Research output: Contribution to journalArticle

Conteduca, V, Sansonno, D, Ingravallo, G, Marangi, S, Russi, S, Lauletta, G & Dammacco, F 2012, 'Barrett's esophagus and esophageal cancer: An overview', International Journal of Oncology, vol. 41, no. 2, pp. 414-424. https://doi.org/10.3892/ijo.2012.1481
Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G et al. Barrett's esophagus and esophageal cancer: An overview. International Journal of Oncology. 2012 Aug;41(2):414-424. https://doi.org/10.3892/ijo.2012.1481
Conteduca, Vincenza ; Sansonno, Domenico ; Ingravallo, Giuseppe ; Marangi, Stefania ; Russi, Sabino ; Lauletta, Gianfranco ; Dammacco, Franco. / Barrett's esophagus and esophageal cancer : An overview. In: International Journal of Oncology. 2012 ; Vol. 41, No. 2. pp. 414-424.
@article{fe3a12d0684748ee994d0d27896265dd,
title = "Barrett's esophagus and esophageal cancer: An overview",
abstract = "Although esophageal cancer (EC) is the eighth most common cancer in several European countries, it is one of deadliest worldwide. The most frequent predisposing factor implicated in its development is Barrett's esophagus (BE), an acquired metaplastic transformation of the esophageal lining cells from normal squamous epithelium into specialised or intestinal-like columnar epithelium. The major risk factor for BE is gastroesophageal reflux disease. Although BE is in itself a benign and often asymptomatic disorder, its clinical importance stems from the recognition that it represents the main precursor lesion for the development of esophageal adenocarcinoma (AC), a tumor that is rapidly increasing especially in developed countries and is associated with a low survival rate. This paper provides an overview of the epidemiology and natural history of BE as well as of the possible pathogenetic mechanisms underlying the development of BE and its progressive transition to AC. New diagnostic tests are described, recommendations for screening and surveillance are provided and surgical and ablative procedures to treat dysplastic lesions and early neoplasia are discussed. Claimed chemopreventive agents and biomarkers that in the near future may help identify people with a higher risk of EC are also considered.",
keywords = "Adenocarcinoma, Barrett's esophagus, Biomarkers, Esophageal cancer, Gastro-esophageal reflux disease, Proton pump inhibitors, Squamous cell carcinoma",
author = "Vincenza Conteduca and Domenico Sansonno and Giuseppe Ingravallo and Stefania Marangi and Sabino Russi and Gianfranco Lauletta and Franco Dammacco",
year = "2012",
month = "8",
doi = "10.3892/ijo.2012.1481",
language = "English",
volume = "41",
pages = "414--424",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Barrett's esophagus and esophageal cancer

T2 - An overview

AU - Conteduca, Vincenza

AU - Sansonno, Domenico

AU - Ingravallo, Giuseppe

AU - Marangi, Stefania

AU - Russi, Sabino

AU - Lauletta, Gianfranco

AU - Dammacco, Franco

PY - 2012/8

Y1 - 2012/8

N2 - Although esophageal cancer (EC) is the eighth most common cancer in several European countries, it is one of deadliest worldwide. The most frequent predisposing factor implicated in its development is Barrett's esophagus (BE), an acquired metaplastic transformation of the esophageal lining cells from normal squamous epithelium into specialised or intestinal-like columnar epithelium. The major risk factor for BE is gastroesophageal reflux disease. Although BE is in itself a benign and often asymptomatic disorder, its clinical importance stems from the recognition that it represents the main precursor lesion for the development of esophageal adenocarcinoma (AC), a tumor that is rapidly increasing especially in developed countries and is associated with a low survival rate. This paper provides an overview of the epidemiology and natural history of BE as well as of the possible pathogenetic mechanisms underlying the development of BE and its progressive transition to AC. New diagnostic tests are described, recommendations for screening and surveillance are provided and surgical and ablative procedures to treat dysplastic lesions and early neoplasia are discussed. Claimed chemopreventive agents and biomarkers that in the near future may help identify people with a higher risk of EC are also considered.

AB - Although esophageal cancer (EC) is the eighth most common cancer in several European countries, it is one of deadliest worldwide. The most frequent predisposing factor implicated in its development is Barrett's esophagus (BE), an acquired metaplastic transformation of the esophageal lining cells from normal squamous epithelium into specialised or intestinal-like columnar epithelium. The major risk factor for BE is gastroesophageal reflux disease. Although BE is in itself a benign and often asymptomatic disorder, its clinical importance stems from the recognition that it represents the main precursor lesion for the development of esophageal adenocarcinoma (AC), a tumor that is rapidly increasing especially in developed countries and is associated with a low survival rate. This paper provides an overview of the epidemiology and natural history of BE as well as of the possible pathogenetic mechanisms underlying the development of BE and its progressive transition to AC. New diagnostic tests are described, recommendations for screening and surveillance are provided and surgical and ablative procedures to treat dysplastic lesions and early neoplasia are discussed. Claimed chemopreventive agents and biomarkers that in the near future may help identify people with a higher risk of EC are also considered.

KW - Adenocarcinoma

KW - Barrett's esophagus

KW - Biomarkers

KW - Esophageal cancer

KW - Gastro-esophageal reflux disease

KW - Proton pump inhibitors

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84863584366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863584366&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1481

DO - 10.3892/ijo.2012.1481

M3 - Article

C2 - 22615011

AN - SCOPUS:84863584366

VL - 41

SP - 414

EP - 424

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -